CHROMOSOMAL ABNORMALITIES IN PHILADELPHIA CHROMOSOME- NEGATIVE CELLS IN PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH FIRST GENERATION TYROSINE KINASE INHIBITOR- SINGLE CENTER EXPERIENCE
Journal
International Journal of Current Research and Review
Date Issued
2013-05-10
Author(s)
Dukovski, Dushko
Popova-Simjanovska Marija
Abstract
Chronic myelogenous leukemia (CML) is characterized by the presence of a Bcr-Abl fusion protein
with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype.
Imatinib as a selective inhibitor of Bcr-Abl induces complete cytogenetic remission in the majority of
patients with CML in chronic phase. Targeted therapy of CML with imatinib favors the manifestation
of Ph-(negative) clone disorders in some patients. Facts indicate that patients on imatinib should be
followed with conventional cytogenetics, even after induction of complete remission.
We report a case of a patient with CML, in chronic phase treated with imatinib which induces the most
common abnormality trisomy 8.
with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype.
Imatinib as a selective inhibitor of Bcr-Abl induces complete cytogenetic remission in the majority of
patients with CML in chronic phase. Targeted therapy of CML with imatinib favors the manifestation
of Ph-(negative) clone disorders in some patients. Facts indicate that patients on imatinib should be
followed with conventional cytogenetics, even after induction of complete remission.
We report a case of a patient with CML, in chronic phase treated with imatinib which induces the most
common abnormality trisomy 8.
File(s)![Thumbnail Image]()
Loading...
Name
CML Sanja.pdf
Size
319.91 KB
Format
Adobe PDF
Checksum
(MD5):543dfc628e7eff143a17c5ce37605ab8